PI-103

PI-103は、強力な、細胞透過性、ATP競争的クラスI PI3K阻害剤で、DNA-PK、 p110α、 mTORC1、 PI3-KC2β、 p110δ、 mTORC2、 p110β、p110γ に作用すると、IC50 がそれぞれ 2 nM、 8 nM、 20 nM、26 nM、 48 nM、 83 nM、 88 nM 、150 nMになる。

価格 在庫  
USD 168 あり
USD 185 あり
USD 340 あり
USD 466 あり

PI-103 化学構造
分子量: 348.36

高品質保証

カスタマーフィードバック(4)

Quality Control & MSDS

製品説明

  • Compare PI3K Inhibitors
    PI3K製品生物活性の比較
  • 研究分野
  • PI-103のメカニズム

製品の説明

生物活性

製品説明 PI-103は、強力な、細胞透過性、ATP競争的クラスI PI3K阻害剤で、DNA-PK、 p110α、 mTORC1、 PI3-KC2β、 p110δ、 mTORC2、 p110β、p110γ に作用すると、IC50 がそれぞれ 2 nM、 8 nM、 20 nM、26 nM、 48 nM、 83 nM、 88 nM 、150 nMになる。
ターゲット p110α p110β p110δ p110γ mTOR DNA-PK
IC50 2 nM 3 nM 3 nM 15 nM 30 nM 23 nM [3]
In vitro試験 PI-103 potently inhibits both the rapamycin-sensitive (mTORC1) and rapamycin-insensitive (mTORC2) complexes of the protein kinase mTOR. [1] PI-103 inhibits constitutive and growth factor-induced PI3K/Akt, as well as mTORC1 activation. [2] In blast cells, PI-103 inhibits leukemic proliferation, the clonogenicity of leukemic progenitors and induces mitochondrial apoptosis, especially in the compartment containing leukemic stem cells. PI-103 inhibits p110α >200-fold more potently than p110β. PI-103 also potently blocks production of PI(3,4)P2 and PIP3 in adipocytes and PIP3 in myotubes. [2] PI-103 inhibits phosphorylation of Akt with an IC95 100-fold lower than that for LY294002. Strikingly, PI-103 completely protects animals from insulin-stimulated decline in blood glucose. PI-103 has additive proapoptotic effects with etoposide in blast cells and in immature leukemic cells. [2]
Cell Data
Cell LinesAssay TypeConcentrationIncubation TimeFormulationActivity DescriptionPMID
SK-N-BE MmrXS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NHnSO2kxNThizszN NGHyOZIzPC92OD:3NkBp MWjpcoR2[2W|IITpcYUuKGGwZDDjc45k\W62cnH0bY9vNWSncHXu[IVvfCCrbnjpZol1cW:wIH;uJG5DKGOnbHyg[5Jwf3Sq M1zXd|I3OjJ2Nkix
SH-SY5Y Mmi0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NGnMcpgxNThizszN NHXweG4zPC92OD:3NkBp M33ie4lv\HWlZYOgeIlu\S1iYX7kJINwdmOnboTyZZRqd25vZHXw[Y5l\W62IHnubIljcXSrb36gc44hVkJiY3XscEBoem:5dHi= MVeyOlIzPDZ6MR?=
SH-SY5Y  NF3qWpVCeG:ydH;zbZMhSXO|YYm= M2j5RlEh|ryP NV;COmxrOC53LUK0JIg> MWnz[Y5{cXSrenXzJI5mfXKxYnzhd5RwdWFiY3XscJMhfG9iZH;4c5J2[mmlaX6tbY5lfWOnZDDhdI9xfG:|aYO= MonFNlYzOjR4OEG=
G 35 SC MXfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MYiwMlA2NTJyIN88US=> NEK2VHMzPC95MjDo NW\aSIdETE2VTx?= MXrpcohq[mm2czDj[YxtKH[rYXLpcIl1gSCmb4PlJIFv\CC2aX3lJIRmeGWwZHXueIx6 M4fZRlI3OTJzMkWx
G 38 SC NES1c2RIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NWrETZZqOC5yNT2yNEDPxE1? NHqwcXczPC95MjDo M3XoPGROW09? M4fjeolvcGmkaYTzJINmdGxidnnhZoltcXS7IHTvd4Uh[W6mIITpcYUh\GWyZX7k[Y51dHl? MYWyOlEzOTJ3MR?=
G 40 SC M1jDVGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MUOwMlA2NTJyIN88US=> MojqNlQwPzJiaB?= Mn:2SG1UVw>? NX;wPG5icW6qaXLpeJMh[2WubDD2bYFjcWyrdImg[I9{\SCjbnSgeIlu\SCmZYDlcoRmdnSueR?= MlHpNlYyOjF{NUG=
G 35 DC MX\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NIX6bYIxNjB3LUKwJO69VQ>? MVWyOE84OiCq MXLEUXNQ NWLwN3h6cW6qaXLpeJMh[2WubDD2bYFjcWyrdImg[I9{\SCjbnSgeIlu\SCmZYDlcoRmdnSueR?= MlHCNlYyOjF{NUG=
G 38 DC Mo\PS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NFO2Z4cxNjB3LUKwJO69VQ>? NX7aZ5VoOjRxN{KgbC=> NVWzfW9ETE2VTx?= MXTpcohq[mm2czDj[YxtKH[rYXLpcIl1gSCmb4PlJIFv\CC2aX3lJIRmeGWwZHXueIx6 M1zLeVI3OTJzMkWx
G 40 DC MY\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NH;iWG0xNjB3LUKwJO69VQ>? MWCyOE84OiCq MVTEUXNQ NHj4cI5qdmirYnn0d{Bk\WyuII\pZYJqdGm2eTDkc5NmKGGwZDD0bY1mKGSncHXu[IVvfGy7 MoPINlYyOjF{NUG=
RD NUHlb2RUSXCxcITvd4l{KEG|c3H5 MXSxM|EvPS9{IN88US=> M2P2UVczKGh? M4HLXolv\HWlZYOgZZBweHSxc3nzJINwdWKrbnXkJJdqfGhiR1HOWFYy Mn7oNlU4PDl|N{i=
TE381.T NXfkcGxOSXCxcITvd4l{KEG|c3H5 NFLpeZgyNzFwNT:yJO69VQ>? MnW1O|IhcA>? MoXSbY5lfWOnczDhdI9xfG:|aYOgZ49u[mmwZXSge4l1cCCJQV7UOlE> NXO2NFJqOjV5NEmzO|g>
RMS13 MmrzRZBweHSxc3nzJGF{e2G7 M2jyT|EwOS53L{Kg{txO MlHOO|IhcA>? NWiySWVEcW6mdXPld{BieG:ydH;zbZMh[2:vYnnu[YQhf2m2aDDHRW5VPjF? M1fx[lI2PzR7M{e4
RH30  NUTVdVBTSXCxcITvd4l{KEG|c3H5 M{DpW|EwOS53L{Kg{txO NGeySIU4OiCq NGPSWlJqdmS3Y3XzJIFxd3C2b4Ppd{Bkd22kaX7l[EB4cXSqIFfBUnQ3OQ>? MYGyOVc1QTN5OB?=
VJ M1\ke2Fxd3C2b4Ppd{BCe3OjeR?= NWXaNoNjOS9zLkWvNkDPxE1? MonwO|IhcA>? MoKzbY5lfWOnczDhdI9xfG:|aYOgZ49u[mmwZXSge4l1cCCJQV7UOlE> NXS4ZpBEOjV5NEmzO|g>
HS578T MWTD[YxtKF[rYXLpcIl1gSCDc4PhfS=> NFLZXpkxNTNizszN NXvlW2EyPzJiaB?= MnLMbY5pcWKrdIOgZ4VtdCC4aXHibYxqfHliZH;z[UBl\XCnbnTlcpRtgQ>? NEDPTVAzPTd{MUSxPS=>
BT549 M3WwPWNmdGxiVnnhZoltcXS7IFHzd4F6 NYPid|doOC1|IN88US=> Mn:xO|IhcA>? NWX2PFVzcW6qaXLpeJMh[2WubDD2bYFjcWyrdImg[I9{\SCmZYDlcoRmdnSueR?= MlvjNlU4OjF2MUm=
MDA-MB-231 Mn\nR4VtdCCYaXHibYxqfHliQYPzZZk> M2\kNFAuOyEQvF2= MnjVO|IhcA>? Mn7EbY5pcWKrdIOgZ4VtdCC4aXHibYxqfHliZH;z[UBl\XCnbnTlcpRtgQ>? MXKyOVczOTRzOR?=
MDA-MB-468 M{\iT2NmdGxiVnnhZoltcXS7IFHzd4F6 MlvQNE0{KM7:TR?= MnHHO|IhcA>? NVu1O5lGcW6qaXLpeJMh[2WubDD2bYFjcWyrdImg[I9{\SCmZYDlcoRmdnSueR?= M{W3T|I2PzJzNEG5
MDA-MB-436 MnW0R4VtdCCYaXHibYxqfHliQYPzZZk> M1\DWFAuOyEQvF2= MUG3NkBp NWnmWm91cW6qaXLpeJMh[2WubDD2bYFjcWyrdImg[I9{\SCmZYDlcoRmdnSueR?= NGLWS4ozPTd{MUSxPS=>
SUM149PT Mn;nR4VtdCCYaXHibYxqfHliQYPzZZk> NEjXdoQxNTNizszN M{PIR|czKGh? Mly3bY5pcWKrdIOgZ4VtdCC4aXHibYxqfHliZH;z[UBl\XCnbnTlcpRtgQ>? MkLCNlU4OjF2MUm=
MDA-MB-468 MUnGeY5kfGmxbjDBd5NigQ>? NXTBfXBxOC5yMT2xNEDPxE1? M130[|I1KGh? MkHW[I94dnKnZ4XsZZRmeyC2aHWgcIV3\Wy|IH;mJO6zNVS{Q2CxMEBkNU27YzDhcoQh[3mlbHnuJGUheHKxdHXpcpPDqA>? MXSyOVczOTRzOR?=
MDA-MB-231 M{HNWGZ2dmO2aX;uJGF{e2G7 MVewMlAyNTFyIN88US=> MVmyOEBp MmDj[I94dnKnZ4XsZZRmeyC2aHWgcIV3\Wy|IH;mJO6zNVS{Q2CxMEBkNU27YzDhcoQh[3mlbHnuJGUheHKxdHXpcpPDqA>? M4fIU|I2PzJzNEG5
HS578T MYjGeY5kfGmxbjDBd5NigQ>? MljFNE4xOS1zMDFOwG0> MYmyOEBp MnjE[I94dnKnZ4XsZZRmeyC2aHWgcIV3\Wy|IH;mJO6zNVS{Q2CxMEBkNU27YzDhcoQh[3mlbHnuJGUheHKxdHXpcpPDqA>? MUeyOVczOTRzOR?=
SW872 Mnv3SpVv[3Srb36gRZN{[Xl? NFjrb3cxNjBzLUCuOUDPxE1? MnvpNlQhcA>? NVL4WVdkemWmdXPld{BCU1RicHjvd5Bpd3K7bHH0bY9vKCiyQVvULUBidmRiNFXCVFEheGixc4Doc5J6dGG2aX;uJEhxPEWEUEGpJIlvKGFiZH;z[U1l\XCnbnTlcpQhdWGwbnXyxsA> MlLINlQ3QTV4M{K=
SW982 MmLUSpVv[3Srb36gRZN{[Xl? MnHHNE4xOS1yLkWg{txO Mn7iNlQhcA>? NFrGbJVz\WS3Y3XzJGFMXCCyaH;zdIhwenmuYYTpc44hMHCDS2SpJIFv\CB2RVLQNUBxcG:|cHjvdplt[XSrb36gLJA1TUKSMTmgbY4h[SCmb4PlMYRmeGWwZHXueEBu[W6wZYNCpC=> NUDtb|ZNOjR4OUW2N|I>
SW872 NFrNNItCeG:ydH;zbZMhSXO|YYm= MmrxNE4xOS1yLkWg{txO MonFOFghcA>? NY[wdVdYcW6mdXPld{BieG:ydH;zbZMh\G:|ZTDk[ZBmdmSnboTsfS=> M4fpRlI1Pjl3NkOy
SW982 NGKxe2ZCeG:ydH;zbZMhSXO|YYm= M17jSVAvODFvMD61JO69VQ>? NFrHbmc1QCCq MmDybY5lfWOnczDhdI9xfG:|aYOg[I9{\SCmZYDlcoRmdnSueR?= NIGyZnkzPDZ7NU[zNi=>
AGS HG NWfUU3BnT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MWjJR|UxRTBwNkigxtEhOC5yM{Gg{txO MYKyOFU6PzR5OB?=
AGS LG Ml;HS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M4jDfGlEPTB;MD6wOUDDuSByLkCwNUDPxE1? M2XzZlI1PTl5NEe4
HGC27 HG MYrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MoqxTWM2OD1yLkO4JOKyKDBwMEKyJO69VQ>? M1PlXFI1PTl5NEe4
HGC27 LG NVHtS5pkT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MV;JR|UxRTBwMEKgxtEhOC5yMESg{txO MYKyOFU6PzR5OB?=
MKN45 HG NV;yOJBKT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NHzEdVRKSzVyPUGuNFEhyrFiMD6wOVEh|ryP M2jqd|I1PTl5NEe4
MKN45 LG NXn6dnh3T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MnniTWM2OD1yLki3JOKyKDBwMEOwJO69VQ>? MWCyOFU6PzR5OB?=
NUGC4 HG M37DU2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NEHMdolKSzVyPUG0MlAhyrFiMz65NVMh|ryP NUn2SZFIOjR3OUe0O|g>
NUGC4 LG NVLhNHVRT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MXnJR|UxRTF2LkCgxtEhPS5|MkGg{txO M2C5U|I1PTl5NEe4
A549 NUKwWIpRTnWwY4Tpc44hSXO|YYm= NVqyTFJSOC5{NT:wMlUwOSEQvF2= NEPDUXUzPCCq NYDLdYNzcW6qaXLpeJMhSWu2IIDoc5NxcG:{eXzheIlwdiC|bHnnbJRtgQ>? NUDTdmZOOjR|NUG0NlU>
H460 MmC3SpVv[3Srb36gRZN{[Xl? MmXrNE4zPS9yLkWvNUDPxE1? MVGyOEBp NHTVdpdqdmirYnn0d{BCc3RicHjvd5Bpd3K7bHH0bY9vKHOuaXfoeIx6 NYfLVJdNOjR|NUG0NlU>
H661 Mmq2SpVv[3Srb36gRZN{[Xl? M4nk[VAvOjVxMD61M|Eh|ryP MYGyOEBp NVTkNW4xcW6qaXLpeJMhSWu2IIDoc5NxcG:{eXzheIlwdiC|aXfubYZq[2GwdHz5 M2[4OFI1OzVzNEK1
SAS MXLGeY5kfGmxbjDBd5NigQ>? MknLNE4zPS9yLkWvNUDPxE1? NIXZOWMzPCCq M1PnfYlvcGmkaYTzJGFsfCCyaH;zdIhwenmuYYTpc44he2mpbnnmbYNidnSueR?= NHPGb|AzPDN3MUSyOS=>
UT5 NFvaUpZHfW6ldHnvckBCe3OjeR?= Ml3wNE4zPS9yLkWvNUDPxE1? NWrZPIUyOjRiaB?= NGrWSZZqdmirYnn0d{BCc3RicHjvd5Bpd3K7bHH0bY9vKHOrZ37p[olk[W62bIm= MlGyNlQ{PTF2MkW=
FaDu MlHiSpVv[3Srb36gRZN{[Xl? M4fQNFAvOjVxMD61M|Eh|ryP MX2yOEBp MojRbY5pcWKrdIOgRYt1KHCqb4PwbI9zgWyjdHnvckB{cWewaX\pZ4FvfGy7 NUjsdHA2OjR|NUG0NlU>
RD MljJRZBweHSxc3nzJGF{e2G7 MoPRNU8yNjVxMjFOwG0> MlXOO|IhcA>? NXfmXGlsTE2VTx?= M4TGNolv\HWlZYOgZ4F{eGG|ZT3k[ZBmdmSnboSgZZBweHSxc3nzJINwdWKrbnXkJJdqfGhiVV:xNlY> MYiyN|Y5PDl{NR?=
TE671 MmXQRZBweHSxc3nzJGF{e2G7 NUDTcGQ4OS9zLkWvNkDPxE1? MV63NkBp NHPa[JpFVVOR M1fnfYlv\HWlZYOgZ4F{eGG|ZT3k[ZBmdmSnboSgZZBweHSxc3nzJINwdWKrbnXkJJdqfGhiVV:xNlY> MXqyN|Y5PDl{NR?=
RH30  Mn7pRZBweHSxc3nzJGF{e2G7 Mn;FNU8yNjVxMjFOwG0> M3\ObVczKGh? NXzuZY1bTE2VTx?= NEHZVZBqdmS3Y3XzJINie3Cjc3Wt[IVx\W6mZX70JIFxd3C2b4Ppd{Bkd22kaX7l[EB4cXSqIGXPNVI3 NFHYS2MzOzZ6NEmyOS=>
RMS13 MX;BdI9xfG:|aYOgRZN{[Xl? NWTEN5ZXOS9zLkWvNkDPxE1? M3v3NVczKGh? NVj3cVBJTE2VTx?= MnSzbY5lfWOnczDjZZNx[XOnLXTldIVv\GWwdDDhdI9xfG:|aYOgZ49u[mmwZXSge4l1cCCXT{GyOi=> M1\5e|I{Pjh2OUK1
SUM149PT MXXD[YxtKF[rYXLpcIl1gSCDc4PhfS=> NIiweogxNjNizszN MmnOO|IhcA>? Mnft[Y5p[W6lZYOgZ5l1d3SxeHnjJIVn\mWldIOgc4YhWEl|Sz;BT3QheGG2aIfhfUBqdmirYnn0c5J{ M4XPVFI{PjBzMEe0
MDA-MB-468 M1rqSmNmdGxiVnnhZoltcXS7IFHzd4F6 MUGwMlMh|ryP NV7Ud5VEPzJiaB?= MkLE[Y5p[W6lZYOgZ5l1d3SxeHnjJIVn\mWldIOgc4YhWEl|Sz;BT3QheGG2aIfhfUBqdmirYnn0c5J{ MUWyN|YxOTB5NB?=
MDA-MB-231 Mon6R4VtdCCYaXHibYxqfHliQYPzZZk> NHTablYxNjNizszN NYewflU2PzJiaB?= NWW5c5BX\W6qYX7j[ZMh[3m2b4TvfIlkKGWoZnXjeJMhd2ZiUFmzT{9CU1RicHH0bJdigSCrbnjpZol1d3K| NXrrN5N3OjN4MEGwO|Q>
SY5Y MXPGeY5kfGmxbjDBd5NigQ>? M{G1O|EvPS9{LkWvOUDPxE1? NEixV3QzPCCq M4PPNolv\HWlZYOgS|HDqGOnbHytZ5lkdGViYYLy[ZN1KGGwZDDhdI9xfG:|aYO= NF7mVZYzOzN5OEO0NS=>
SKNBE(2c) MUfGeY5kfGmxbjDBd5NigQ>? M2rWTVEvPS9{LkWvOUDPxE1? MYqyOEBp MlfQbY5lfWOnczDHNeKh[2WubD3jfYNt\SCjcoLld5Qh[W6mIHHwc5B1d3Orcx?= MWOyN|M4QDN2MR?=
RD MWLBdI9xfG:|aYOgRZN{[Xl? MmTON{DDvU1? MXSxNkBp NHHHWHJFVVOR M2C2bpNmdnOrdHn6[ZMhWkRiY3XscJMhfG9iRF;YMYlv\HWlZXSgZZBweHSxc3nz NGWwfowzOzNyMEiwPS=>
TP5014 MlfIRZBweHSxc3nzJGF{e2G7 NGP6Uog{KML3TR?= MUixNkBp MYLEUXNQ M{\ZTpNmdnOrdHn6[ZMhWkRiY3XscJMhfG9iRF;YMYlv\HWlZXSgZZBweHSxc3nz MnXqNlM{ODB6MEm=
HT1080 NH\UbY5CeG:ydH;zbZMhSXO|YYm= M13WPVMhyrWP NF;BTlMyOiCq NX;4d5pPTE2VTx?= MWXz[Y5{cXSrenXzJHJFKGOnbHzzJJRwKESRWD3pcoR2[2WmIHHwc5B1d3Orcx?= MYSyN|MxODhyOR?=
A549 NW\YcHAxTnWwY4Tpc44hSXO|YYm= MlLhNE0{NjNizszN NHXINXc4OiCq M2fMTolv\HWlZYOgZ49ueGyndHWg[I94dnKnZ4XsZZRqd25ib3[gdGFMXA>? M2HXd|I{OjV7NUmx
HCC827 MoPISpVv[3Srb36gRZN{[Xl? M{W4bFAuOy5|IN88US=> MXu3NkBp NH;FepNqdmS3Y3XzJINwdXCuZYTlJIRwf26{ZXf1cIF1cW:wIH;mJJBCU1R? M3zhNVI{OjV7NUmx
H3122 Ml\kSpVv[3Srb36gRZN{[Xl? MVywMVMvOyEQvF2= NHLPdVg4OiCq M4X3bYlv\HWlZYOgZ49ueGyndHWg[I94dnKnZ4XsZZRqd25ib3[gdGFMXA>? MoL3NlMzPTl3OUG=
TALL-1 M3HOV2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M2nJeVHjiIoQvF2= MUi3JIQ> Mmfs[IVkemWjc3XzJJRp\SClZXzsJI52dWKncjDzbYdvcW[rY3HueIx6 MWGyN|A{QDJ5Mx?=
HPB-ALL MkH1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NX\LeFZjOeLCid88US=> NUL5fZhjPyCm M1S5bIRm[3KnYYPld{B1cGViY3XscEBvfW2kZYKgd4lodmmoaXPhcpRtgQ>? NF\neGYzOzB|OEK3Ny=>
DND41 MWjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mon5NgKBkc7:TR?= M3\iNFch\A>? NGfMfXZl\WO{ZXHz[ZMhfGinIHPlcIwhdnWvYnXyJJNq\26rZnnjZY51dHl? MY[yN|A{QDJ5Mx?=
SUP-T1 NGLUdHRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NXniSJZ4OeLCid88US=> M1fxO|ch\A>? NWjQV4JC\GWlcnXhd4V{KHSqZTDj[YxtKG63bXLldkB{cWewaX\pZ4FvfGy7 MojLNlMxOzh{N{O=
PEER NYTYV3JLT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MXmx5qCK|ryP MXK3JIQ> NHjDNWpl\WO{ZXHz[ZMhfGinIHPlcIwhdnWvYnXyJJNq\26rZnnjZY51dHl? NETONFYzOzB|OEK3Ny=>
ALL-SIL NEXkd21Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NFzsSWYy6oDLzszN NYXnWGh5PyCm NIG0NZJl\WO{ZXHz[ZMhfGinIHPlcIwhdnWvYnXyJJNq\26rZnnjZY51dHl? MWiyN|A{QDJ5Mx?=
KE37 MkHwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MYKx5qCK|ryP NHHqd3U4KGR? MUTk[YNz\WG|ZYOgeIhmKGOnbHygcpVu[mW{IIPp[45q\mmlYX70cJk> MXWyN|A{QDJ5Mx?=
Karpas-45 NFKyUmdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NEW4bGMy6oDLzszN Ml7qO{Bl MmLy[IVkemWjc3XzJJRp\SClZXzsJI52dWKncjDzbYdvcW[rY3HueIx6 M1y4Z|I{ODN6Mkez
RPMI-8402 MUTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NXjZe2JJOeLCid88US=> M{Ts[Vch\A>? MkLu[IVkemWjc3XzJJRp\SClZXzsJI52dWKncjDzbYdvcW[rY3HueIx6 NWjJWFJJOjNyM{iyO|M>
Jurkat M1PZRWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NHHsUI4y6oDLzszN NVexTmVRPyCm NUjONXpF\GWlcnXhd4V{KHSqZTDj[YxtKG63bXLldkB{cWewaX\pZ4FvfGy7 MU[yN|A{QDJ5Mx?=
MOLT-4 NW\iVVJwT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MkfuNgKBkc7:TR?= MkL4O{Bl M2jvPIRm[3KnYYPld{B1cGViY3XscEBvfW2kZYKgd4lodmmoaXPhcpRtgQ>? NHXrem4zOzB|OEK3Ny=>
PF-382 M3PBVWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M4HwN|HjiIoQvF2= MWK3JIQ> Ml:0[IVkemWjc3XzJJRp\SClZXzsJI52dWKncjDzbYdvcW[rY3HueIx6 M3HGe|I{ODN6Mkez
CCRF-CEM MXvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MoPrNgKBkc7:TR?= MlT3O{Bl NX;vN3cx\GWlcnXhd4V{KHSqZTDj[YxtKG63bXLldkB{cWewaX\pZ4FvfGy7 MXuyN|A{QDJ5Mx?=
LOUCY NHfVb5NIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NIT0SFUy6oDLzszN MnHXO{Bl MWjk[YNz\WG|ZYOgeIhmKGOnbHygcpVu[mW{IIPp[45q\mmlYX70cJk> MkSzNlMxOzh{N{O=
MOLT-16 M1fsfGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NH\ibW8y6oDLzszN NF3ofo04KGR? NUiwdWpv\GWlcnXhd4V{KHSqZTDj[YxtKG63bXLldkB{cWewaX\pZ4FvfGy7 MWCyN|A{QDJ5Mx?=
MM1S M{HDfWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M4[wTlAuOiEQvF2= M{PEc|I1KGh? M4HEemlEPTB;MD61JO69VQ>? MX6yNlgzQTJ|NB?=
NCI-H929 NEjDRpJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3ewdVAuOiEQvF2= M2LleVI1KGh? NX:ydpZIUUN3ME2wMlI2KM7:TR?= MX[yNlgzQTJ|NB?=
KMS12-BM  NX3BclBHT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MX[wMVIh|ryP NVz3cVk2OjRiaB?= NWjOR|dmUUN3MP-8olIh|ryP MXGyNlgzQTJ|NB?=
MDA-MB-436 M33hZmZ2dmO2aX;uJGF{e2G7 NVjufZVWOSEQvF2= NFzrepgzPCCq NVPOdFlPemWmdXPld{B1cGVicHjvd5Bpd3K7bHH0bY9vKG:oIFHLWC=> NFvvRpUzOjR6OEW5NC=>
SUM149PT MlPKSpVv[3Srb36gRZN{[Xl? MoDxNUDPxE1? NH73VGwzPCCq NWK5cHI2emWmdXPld{B1cGVicHjvd5Bpd3K7bHH0bY9vKG:oIFHLWC=> MYmyNlQ5QDV7MB?=
SUM1315MO2 M2LNcWZ2dmO2aX;uJGF{e2G7 MUmxJO69VQ>? M4PrOlI1KGh? MkjkdoVlfWOnczD0bIUheGixc4Doc5J6dGG2aX;uJI9nKEGNVB?= M3H4W|IzPDh6NUmw
HCC1937 MX;GeY5kfGmxbjDBd5NigQ>? NWnWeVg1OSEQvF2= NIP6fnozPCCq Mmq2doVlfWOnczD0bIUheGixc4Doc5J6dGG2aX;uJI9nKEGNVB?= NF7ZfHYzOjR6OEW5NC=>
HCC827 M3TBWmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MV[wMVMh|ryP M1TJclczKGh? MlX6TWM2OD1yLkOg{txO M1rDPFIyOjJyNEe0
PC-9  M3TybWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NWrTeG5wOC1|IN88US=> MV63NkBp NI\icoFKSzVyPUCuPEDPxE1? NHjGdmozOTJ{MES3OC=>
LN229 MkjISpVv[3Srb36gRZN{[Xl? MWCxJO69VQ>? NULRepFpPDhiaB?= NHjrPGpqdmS3Y3XzJIF2fG:yaHHnc5NwdWViZn;ycYF1cW:w M123d|IyODZ{OUmz
U87 MU\GeY5kfGmxbjDBd5NigQ>? NF;1[XkyKM7:TR?= MW[0PEBp Mk\ObY5lfWOnczDheZRweGijZ3;zc41mKG[xcn3heIlwdg>? M{LUUFIyODZ{OUmz
U373 NELhO4dHfW6ldHnvckBCe3OjeR?= NHzRb5YyKM7:TR?= M3;0SlQ5KGh? MULpcoR2[2W|IHH1eI9xcGGpb4PvcYUh\m:{bXH0bY9v NGf1cJMzOTB4Mkm5Ny=>
SF767 NUjDNJNRTnWwY4Tpc44hSXO|YYm= MXixJO69VQ>? MlzhOFghcA>? MWrpcoR2[2W|IHH1eI9xcGGpb4PvcYUh\m:{bXH0bY9v M2e3TVIyODZ{OUmz
Mel-Juso NUTaR|R7S2WubDDWbYFjcWyrdImgRZN{[Xl? M3rOcFAvODIkgKOxNQKBkc7:TR?= MUK3NkBp MYTpcohq[mm2czDj[YxtKH[rYXLpcIl1gSCmb4PlJIRmeGWwZHXueIx6 M4jFc|IyODR6N{i1
518A2  NEHmUpJE\WyuIG\pZYJqdGm2eTDBd5NigQ>? NWrWWJkzOC5yMfMAl|Ex6oDLzszN MlTwO|IhcA>? MmH3bY5pcWKrdIOgZ4VtdCC4aXHibYxqfHliZH;z[UBl\XCnbnTlcpRtgQ>? NIHv[GIzOTB2OEe4OS=>
Mel-Juso  MonKSpVv[3Srb36gRZN{[Xl? MXWwMlAxOeLCk{JihKnPxE1? M2D6VFI1KGh? NGq2WXV{fXCycnXzd4V{KHCqb4PwbI9zgWyjdHnvckBw\iCyaH;zdIhifGmmeXygbY5we2m2b3ygN{1scW6jc3Wg[I94dnO2cnXhcUB1[XKpZYTz MlHhNlExPDh5OEW=
518A2 MYLGeY5kfGmxbjDBd5NigQ>? MoL4NE4xODIkgKOx5qCK|ryP NGXHUIozPCCq NXzrc5VTe3WycILld5NmeyCyaH;zdIhwenmuYYTpc44hd2ZicHjvd5Bp[XSrZInsJIlvd3OrdH;sJFMuc2mwYYPlJIRwf26|dILlZY0hfGG{Z3X0dy=> Mnm5NlExPDh5OEW=
PC3  MljNS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NYX1bJllOjSq MUHHTVUxyqB;IEGwNEBvVQ>? NFHyXW8zODV3MUC2NS=>
U87MG NFLveVNHfW6ldHnvckBCe3OjeR?= NVPDTZVQOC5zLUGg{txO M1rKZ|I16oDLaNMg MXTEUXNQ M{Hl[YlvcGmkaYTzJHBKO0tvbXXkbYF1\WRic3nncoFtcW6p MXOxPVY{OzZ6Mx?=
U138MG M{TtemZ2dmO2aX;uJGF{e2G7 MUewMlEuOSEQvF2= NEXY[mgzPOLCiXlCpC=> NUfL[Y5DTE2VTx?= M3XCbolvcGmkaYTzJHBKO0tvbXXkbYF1\WRic3nncoFtcW6p M3PINlE6PjN|Nkiz
U118MG MorsSpVv[3Srb36gRZN{[Xl? MX:wMlEuOSEQvF2= NVG3W|FiOjUkgJnoxsA> M1HxdmROW09? M{HVTIlvcGmkaYTzJHBKO0tvbXXkbYF1\WRic3nncoFtcW6p MV6xPVY{OzZ6Mx?=
U87MG MU\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NYDhPVh4UUN3ME2wMlE1KM7:TR?= NXP1VZJEOTl3OESyNlc>
IGROV-1 MYTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NF7ONpFKSzVyPUCuNFYh|ryP MWOxPVU5PDJ{Nx?=
DETROIT562 NWHieGw6T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mmr2TWM2OD1yLkGzJO69VQ>? MmnRNVk2QDR{Mke=
PC3  NFP5dXVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NUezcGlsUUN3ME2wMlExKM7:TR?= NVPZZWFSOTl3OESyNlc>
SKOV-3 M3TPfGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1O1NmlEPTB;MD6xNkDPxE1? MoG4NVk2QDR{Mke=
HUVEC MWfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MXLJR|UxRTBwMEig{txO NVfKSWJLOTl3OESyNlc>
UCH-1  NICydWpHfW6ldHnvckBCe3OjeR?= MkKzNE02KM7:TR?= NIrNfZJqdmirYnn0d{B1cGVicHjvd5Bpd3K7bHH0bY9vKG:oIHLveIghSUuWIHHu[EBuXE:UIHnuJIEh\G:|ZT3k[ZBmdmSnboSgcYFvdmW{ NWHibpdXOTl3Mki0OFE>
UCH-1  NYLJN4JlT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MlvaNE4xOS1zMDFOwG0> MX:2JIQ> MXXpcohq[mm2czDwdo9tcW[ncnH0bY9vKGSxc3Wg[IVx\W6mZX70cJk> M{TqNFE6PTJ6NESx
UCH-1  NEOwclRCeG:ydH;zbZMhSXO|YYm= NWPBd45[OC5zLUGwJO69VQ>? MlvCNlQhcA>? M4Pp[2ROW09? MnvTbY5lfWOnczDhdI9xfG:|aYO= NGjWT4YyQTV{OES0NS=>

... Click to View More Cell Line Experimental Data

In vivo試験 When tumors reach 50-100 mm3, animals are randomized and treated with vehicle or PI-103. PI-103 exhibits significant activity, decreasing average tumor size by 4-fold after 18 days. [2] Mice treated with PI-103 have no obvious signs of toxicity premorbidly (based on body weight, food and water intake, activity, and general exam) or at necropsy. Treated tumors display decreased levels of phosphorylated Akt and S6, consistent with blockade of p110α and mTOR. PI-103 treatment is cytostatic to glioma xenografts. [2]
臨床試験
特集 The first potent, synthetic mTOR inhibitor.

プロトコル (参考用のみ)

キナーゼアッセイ: [3]

Enzyme Assays Phosphatidylinositide 3-kinase inhibitory activity was determined using a scintillation proximity assay in the presence of 1 μmol/L ATP. Inhibition of mTOR protein kinase was determined using a TR-FRET-based LanthaScreen method from Invitrogen. Compounds were assayed at a maximum concentration of 10 μmol/L in the presence of 1 μmol/L ATP, and IC50 values were determined using GraphPad Prism software.

細胞アッセイ: [2]

細胞株 U87MG cells
濃度 0.5 μM
反応時間 24 hours
実験の流れ U87MG cells are treated with PI-103 for 24 hours. Cell death is quantified by colorimetric determination of LDH activity using a cytotoxicity detection kit. Percentage of cell death (mean of three 12-well plates per experimental point) is calculated [(experimental value- low control)/(high control -low control) × 100], where the low-control cells are DMSO treated and high-control cells are Triton treated (1% Triton X-100, 30 min, 37 °

動物実験: [2]

動物モデル 6- to 12-week-old Balbc nu/nu mice bearing U87MG:ΔEGFR cells
製剤 50% DMSO
投薬量 5 mg/kg
投与方法 Administered via i.p.

Conversion of different model animals based on BSA (Value based on data from FDA Draft Guidelines)

SpeciesMouseRatRabbitGuinea pigHamsterDogMonkeyBaboon
Weight (kg)0.020.151.80.40.0810312
Body Surface Area (m2)0.0070.0250.150.050.020.50.240.6
Km factor361285201220
Animal A (mg/kg) = Animal B (mg/kg) multiplied by  Animal B Km
Animal A Km

For example, to modify the dose of resveratrol used for a mouse (22.4 mg/kg) to a dose based on the BSA for a rat, multiply 22.4 mg/kg by the Km factor for a mouse and then divide by the Km factor for a rat. This calculation results in a rat equivalent dose for resveratrol of 11.2 mg/kg.

Rat dose (mg/kg) = mouse dose (22.4 mg/kg) ×  mouse Km(3)  = 11.2 mg/kg
rat Km(6)
1

参考

化学情報

Download PI-103 SDF
分子量 348.36
化学式

C19H16N4O3

CAS No. 371935-74-9
保管 2年-20℃
6月-80℃in solvent
別名 N/A
溶解度 (25°C) * In vitro DMSO 24 mg/mL (68.89 mM)
<1 mg/mL (<1 mM)
エタノール <1 mg/mL (<1 mM)
In vivo 1% DMSO/30% polyethylene glycol/1% Tween 80 30 mg/mL
* <1 mg/ml means slightly soluble or insoluble.
* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.
化学名 Phenol, 3-[4-(4-morpholinyl)pyrido[3',2':4,5]furo[3,2-d]pyrimidin-2-yl]-

カスタマーフィードバック (4)


Click to enlarge
Rating
Source Mol Carcinog, 2012, 52, 667-75 . PI-103 purchased from Selleck
Method Western blot
Cell Lines MCF7 cells
Concentrations 0-1 μM
Incubation Time 24 h
Results In BRCA1-KD MCF7 cells, treatment of PI-103, a PI3K/mTOR inhibitor, abolished phosphorylation of AKT and its substrate GSK3b, in a dose dependent manner (Figure A). Treatment of PI-103 reduced the phosphorylation of AKT in all BRCA1 mutant breast cancer cells tested (Figure B). Phosphorylations of downstream targets of AKT, such as phospho-GSK3b (S9) and phospho-BAD(S112) were also reduced by PI-103 treatment. Phosphorylation of mTOR at S2448, which is also known to be phosphorylated by AKT, was also reduced by PI-103 resulting in reduced phosphorylation of S6 ribosomal protein at S235/236 (Figure B). The effect of PI-103 was much more potent than LY294002 in MDA-MB-436 cells (Figure B)

Click to enlarge
Rating
Source Mol Carcinog, 2012, ahead of print. PI-103 purchased from Selleck
Method MTT assay
Cell Lines MCF7 cells
Concentrations 0.01-1 μM
Incubation Time 48 h
Results Knockdown of BRCA1 can sensitize the MCF7 cells to Perifosine in a dose-dependent manner (Figure A). BRCA1-KD also sensitizes the MCF7 cells to dual PI3K/mTOR inhibitors, such as PI-103 or BEZ235 (Figure B, D). Another inhibitor, PIK-75 which specifically inhibits PI3Ka and PI3Kg, but not mTOR, also showed similar effects on proliferation of BRCA1-KD MCF7 cells (Figure C).

Click to enlarge
Rating
Source Dr. Zhang of Tianjin Medical University. PI-103 purchased from Selleck
Method Western blot
Cell Lines Breast cancer cells
Concentrations 0-1 nM
Incubation Time 24 h
Results PI-103 treatment resulted in a reduction of Akt phosphorylation in Breast cancer cells.

Click to enlarge
Rating
Source Saraswati Sukumar of Johns Hopkins University School of Medicine, PI-103 purchased from Selleck
Method Western blot
Cell Lines T47D cells
Concentrations
Incubation Time 1 h
Results PI-103 treatment resulted in a reduction of Akt phosphorylation in T47D cells.

文献中の引用 (21)

技術サポート&よくある質問(FAQ)

ストックの作り方、阻害剤の保管する方法、細胞実験や動物実験に注意すべきな点を全部含めており、製品を取扱う時よくあった質問に対して取扱説明書でお答えいたします。

電話番号: +1-832-582-8158 Ext:3月曜日〜金曜日 9:00 AM–5:00 PM (米国中部標準時)

他の質問がある場合は、お気軽くお問合せください。

* 必須

Related PI3K 阻害剤

  • GDC-0032

    GDC-0032 is a potent, next-generation PI3K inhibitor targeting PI3K alpha.

    Features:A beta isoform-sparing PI3K inhibitor.

  • Pilaralisib (XL147)

    Pilaralisib (XL147) is a selective and reversible class I PI3K inhibitor for PI3Kα/δ/γ with IC50 of 39 nM/36 nM/23 nM in cell-free assays, less potent to PI3Kβ. Phase 1/2.

  • GNE-317

    GNE-317 is a potent, brain-penetrant PI3K inhibitor.

  • PI-3065

    PI-3065 is a selective p110δ inhibitor with IC50 of 15 nM, >70-fold selectivity over other PI3K family members.

  • LY294002

    LY294002は、p110α、p110δとp110βのPI3K阻害剤で、IC50 がそれぞれ 0.5 μM、0.57 μM、0.97 μMです。

  • 3-Methyladenine (3-MA)

    3-Methyladenine (3-MA) は選択の自噬とリン酸イノシトール3キナーゼ(キナーゼ)阻害剤、Vps34 と PI3Kγ に作用する時、 IC50 がそれぞれ 25 nM と 60 nM になる。自動食物胞の形成を妨害すること。

  • CAL-101 (Idelalisib, GS-1101)

    CAL-101 (Idelalisib, GS-1101)は、2.5nMのIC50によるp110δの選択的なPI3KクラスI阻害剤です。

  • Wortmannin

    ワートマニンはミオシン軽鎖キナーゼ(MLCK)のマルチターゲットの阻害剤、IC50がぞれぞれ0.17μMと3nMになる。自動食物胞の形成を妨害すること。

  • BEZ235 (NVP-BEZ235, Dactolisib)

    BEZ235 (NVP-BEZ235, Dactolisib)は競争性的なPI3K、mTOR 阻害剤、 p110α, p110γ, p110δ と p110β を作用すると、 IC50 がぞれぞれ 4 nM, 5 nM, 7 nM と 75 nMになる.

  • BKM120 (NVP-BKM120, Buparlisib)

    BKM120 (NVP-BKM120, Buparlisib)は、p110α、p110β、p110δとp110γの選択的なPI3K阻害剤で、IC50 がそれぞれ 52-99 nM、166 nM、 116 nM、 262 nMです。

最近チェックしたアイテム

Tags: PI-103を買う | PI-103供給者 | PI-103を購入する | PI-103費用 | PI-103生産者 | オーダーPI-103 | PI-103代理店
×
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
お問い合わせ